Abstract
The concept of intramembrane receptor-receptor interactions and evidence for their existences were introduced in the beginning of the 1980's, suggesting the existence of receptor heterodimerization. The discovery of GPCR heteromers and the receptor mosaic (higher order oligomers, more than two) has been related to the parallel development and application of a variety of resonance energy transfer techniques such as bioluminescence (BRET), fluorescence (FRET) and sequential energy transfer (SRET). The assembly of interacting GPCRs, heterodimers and receptor mosaic leads to changes in the agonist recognition, signaling, and trafficking of participating receptors via allosteric mechanisms, sometimes involving the appearance of cooperativity. The receptor interface in the GPCR heteromers is beginning to be characterized and the key role of electrostatic epitope-epitope interactions for the formation of the receptor heteromers will be discussed. Furthermore, a “guide-and-clasp” manner of receptor-receptor interactions has been proposed where the “adhesive guides” may be the triplet homologies. These interactions probably represent a general molecular mechanism for receptor-receptor interactions. It is proposed that changes in GPCR function (moonlighting) may develop through the intracellular loops and C-terminii of the GPCR heteromers as a result of dynamic allosteric interactions between different types of G proteins and other receptor interacting proteins in these domains of the receptors. The evidence for the existence of receptor heteromers opens up a new field for a better understanding of neurophysiology and neuropathology. Furthermore, novel therapeutic approaches could be possible based on the use of heteromers as targets for drug development based on their unique pharmacology
Keywords: Receptor mosaic, oligomers, allosteric modulation, GPCR, receptor recognition, receptor signaling, receptor interface, receptor trafficking, receptor G protein coupling, moonlighting, triplet homologies, adenosine receptor, dopamine receptors
Current Medicinal Chemistry
Title: GPCR Heteromers and their Allosteric Receptor-Receptor Interactions
Volume: 19 Issue: 3
Author(s): K. Fuxe, D. O. Borroto-Escuela, D. Marcellino, W. Romero-Fernandez, M. Frankowska, D. Guidolin, M. Filip, L. Ferraro, A.S. Woods, A. Tarakanov, F. Ciruela, L. F. Agnati and S. Tanganelli
Affiliation:
Keywords: Receptor mosaic, oligomers, allosteric modulation, GPCR, receptor recognition, receptor signaling, receptor interface, receptor trafficking, receptor G protein coupling, moonlighting, triplet homologies, adenosine receptor, dopamine receptors
Abstract: The concept of intramembrane receptor-receptor interactions and evidence for their existences were introduced in the beginning of the 1980's, suggesting the existence of receptor heterodimerization. The discovery of GPCR heteromers and the receptor mosaic (higher order oligomers, more than two) has been related to the parallel development and application of a variety of resonance energy transfer techniques such as bioluminescence (BRET), fluorescence (FRET) and sequential energy transfer (SRET). The assembly of interacting GPCRs, heterodimers and receptor mosaic leads to changes in the agonist recognition, signaling, and trafficking of participating receptors via allosteric mechanisms, sometimes involving the appearance of cooperativity. The receptor interface in the GPCR heteromers is beginning to be characterized and the key role of electrostatic epitope-epitope interactions for the formation of the receptor heteromers will be discussed. Furthermore, a “guide-and-clasp” manner of receptor-receptor interactions has been proposed where the “adhesive guides” may be the triplet homologies. These interactions probably represent a general molecular mechanism for receptor-receptor interactions. It is proposed that changes in GPCR function (moonlighting) may develop through the intracellular loops and C-terminii of the GPCR heteromers as a result of dynamic allosteric interactions between different types of G proteins and other receptor interacting proteins in these domains of the receptors. The evidence for the existence of receptor heteromers opens up a new field for a better understanding of neurophysiology and neuropathology. Furthermore, novel therapeutic approaches could be possible based on the use of heteromers as targets for drug development based on their unique pharmacology
Export Options
About this article
Cite this article as:
Fuxe K., O. Borroto-Escuela D., Marcellino D., Romero-Fernandez W., Frankowska M., Guidolin D., Filip M., Ferraro L., Woods A.S., Tarakanov A., Ciruela F., F. Agnati L. and Tanganelli S., GPCR Heteromers and their Allosteric Receptor-Receptor Interactions, Current Medicinal Chemistry 2012; 19 (3) . https://dx.doi.org/10.2174/092986712803414259
DOI https://dx.doi.org/10.2174/092986712803414259 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Disruption of the Keap1-Containing Ubiquitination Complex as an Antioxidant Therapy
Current Topics in Medicinal Chemistry The Role of Cytochrome P450 Enzymes in the Metabolism of Risperidone and Its Clinical Relevance for Drug Interactions
Current Drug Targets Melatonin Redox Activity. Its Potential Clinical Applications in Neurodegenerative Disorders
Current Topics in Medicinal Chemistry Pharmacology of Sigma (σ) Receptor Ligands from a Behavioral Perspective
Current Pharmaceutical Design 2(3H)-Benzoxazolone and Bioisosters as “Privileged Scaffold” in the Design of Pharmacological Probes
Current Medicinal Chemistry Machine Learning Approaches in Parkinson’s Disease
Current Medicinal Chemistry Xanthine Derivatives as Agents Affecting Non-dopaminergic Neuroprotection in Parkinson’s Disease
Current Medicinal Chemistry Applications of Nanotechnology in Diagnostics and Therapeutics of Alzheimer’s and Parkinson’s Disease
Current Drug Metabolism Olanzapine Loaded Cationic Solid Lipid Nanoparticles for Improved Oral Bioavailability
Current Nanoscience Autism Spectrum Disorders: Etiology and Pharmacotherapy
Current Drug Therapy Drug Repositioning for Treatment of Movement Disorders: From Serendipity to Rational Discovery Strategies
Current Topics in Medicinal Chemistry Alpha7 Neuronal Nicotinic Receptors as Targets for Novel Therapies to Treat Multiple Domains of Schizophrenia
Current Pharmaceutical Biotechnology Immune Defence Mechanisms: Comparing Upper and Lower Airways in Chronic Airway Diseases
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Functional MRI of the Pancreaticobiliary System
Current Medical Imaging In Vitro Metabolism Studies of New Adenosine A Receptor Antagonists
Drug Metabolism Letters Neural Stem Cells: From Neurobiology to Clinical Applications
Current Pharmaceutical Biotechnology Development of Tablet Device App for Parkinson’s Disease Patients’ Continuous Self-Monitoring and Management
Neuroscience and Biomedical Engineering (Discontinued) Enhanced α-Synuclein Expression in Human Neurodegenerative Diseases: Pathogenetic and Therapeutic Implications
Current Protein & Peptide Science Metabolomics of Exhaled Breath Condensate by Nuclear Magnetic Resonance Spectroscopy and Mass Spectrometry: A Methodological Approach
Current Medicinal Chemistry The Role of Neurogenesis in Neurodegenerative Diseases and its Implications for Therapeutic Development
CNS & Neurological Disorders - Drug Targets